GLG News by Rituxan Prescribers: Hematologists (US)

"Under the agreement, Bristol-Myers will pay Exelixis $195 million now and another $45 million in 2009 to codevelop the drugs, known as XL184 and XL281"

Despite my initial reservations Re: too frequent administrations, this is a blockbuster that is not only effective but relatively non toxic.

Britain is reticent to pay for Sutent which will prolong the patients life by months.....

This article pertains to quality, accrual and safety, but in addition....

The exact quote is " Avastin, could raise the risk of blood clots by about 12 percent."

An oral agent that can be used in patients with ITP that have become refractory to steroids, splenectomy and various immunologic manipulations.

A VEGF inhibitor that appears to work well with chemo in non small cell lung carcinoma.

"New data from pivotal FLEX study reveal that patients treated with Erbitux who develop early skin rash show median overall survival of 15 months (p<0.001)" This is the trial that showed Erbitux + chemo prolonged survival minimally when compared to chemo alone. Now we know the ones who develop a...

Tarceva can maintain a remission in non small cell lung cancer after initial therapy with other agents. Just like Lilly's Alimta

Addition of Zevalin after a CR or PR in low grade, follicular lymphomas adds to CR rates and improves time to progression. The implication is that this will result in improved survivals.